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Background: Prostate cancer (PCa) is increasingly recognized as part of hereditary cancer syndromes (HCS). 
HCS prevalence among diverse probands seeking genetic evaluation with PCa family history (FHx) has not been 
reported and has implications for cascade genetic testing (CGT).   
Objective: Evaluate rates of HCS among probands reporting PCa FHx and germline mutations among probands.   
Design, Settings and Participants:  Prospective genetic testing database queried for individuals with PCa FHx. 
Pedigrees analyzed for three HCS: hereditary breast and ovarian cancer [HBOC], Hereditary PCa [HPC], Lynch 
syndrome [LS].  
Outcome Measurements and Statistical analysis: Associations between HCS overall and with plausible link to 
PCA FHx and race evaluated using Fisher’s exact test. Germline mutation rates described among probands 
with suspicion of HCS connected with PCa FHx.   
Results and Limitations: 345 probands reported PCa FHx: 53 African-American (AA), 292 Caucasian (Wh). 
Overall, 220 probands (63.8%) met criteria for at least one HCS with potential link to PCa FHx (75.5% AA; 
61.6% Wh). HBOC linked to PCa FHx was identified in a higher percentage of AA than Wh probands (90.2% vs. 
74.6%, p=0.04). Among probands who underwent genetic testing with any HCS potentially linked to PCa FHx 
(n=169), 19.5% had germline mutations identified; 5 AA probands had germline mutations (all in BRCA1/2) 
while 28 Wh probands had mutations in a spectrum of genes.   
Conclusion: A significant percentage of AA probands with PCa FHx meet criteria for HCS, with HBOC identified 
at the highest rate.  Though limited in sample size, our findings implicate BRCA mutations in AA families with 
HCS linked with PCa, underscoring the need for greater enrollment of AA participants in genetic studies.   
 
Patient Summary: Hereditary cancer syndromes potentially linked to prostate cancer are common in patients 
reporting a family history of prostate cancer. African-American patients may need special attention with 
3 | P a g e  
 
 
regards to testing for hereditary breast and ovarian cancer syndrome which may impact men with prostate 
cancer in these families. 
 
Keywords: Prostate cancer, genetic testing, hereditary cancer syndrome, lynch syndrome, HBOC, BRCA1, 
BRCA2 
 
Twitter Statement: @tchandra_uromd @vedangiri @KimmelCancerCtr shed light on race-specific HCS in 
patients with a family history of #prostatecancer.  




 Prostate cancer (PCa) has a significant heritable component.1  A family history (FHx) of PCa in first-
degree male relatives has been consistently shown to increase the risk of PCa development.1,2 Furthermore, 
PCa has been implicated in multiple hereditary cancer syndromes (HCS) including hereditary PCa (HPC), 
hereditary breast and ovarian cancer (HBOC), and Lynch syndrome (LS).3-9 These expanded insights into the 
syndromic link of PCa has increased the awareness that PCa can be genetically connected to a spectrum of 
cancers in families, which is important to inform genetic testing of probands and cascade genetic testing (CGT) 
of men with PCa in families.3,4  
 Multigene testing has now enabled testing of multiple cancer risks and HCS in probands.10,11 
Commercial labs offer multigene panels that encompass risks for a spectrum of cancers, and probands seeking 
hereditary cancer evaluation typically can choose focused cancer testing or large cancer panels based upon 
personal history, FHx, and patient preference.10  FHx in particular can lead to broader gene testing in probands 
beyond their presenting cancer risk concern to encompass the cancers reported in families for greater chance 
of identifying a genetic basis for cancers occurring in a family, inform screening, and guide CGT. Information 
on PCa FHx is therefore critical to factor in to hereditary cancer discussions with probands, and has not been 
historically significant prior to recent genetic insights and expanded genetic testing capability for inherited 
PCa.4,12,13 Indeed, multiple genes associated with HBOC, HPC, and LS lend varying degree of risk for inherited 
PCa and include BRCA1, BRCA2, MLH1, MSH2, PMS2, MSH6, and HOXB13.1,4  Furthermore, men with PCa have 
been shown to carry a spectrum of germline mutations in DNA repair genes, several of which are associated 
with disease aggressiveness.4,12-16 NCCN guidelines have also significantly expanded to address multigene 
testing for men with PCa with the recognition of the impact on CGT in families.8,9 Therefore, intake of PCa FHx 
from female and male probands is essential to guide extent of genetic testing, uncover cancer risks, and 
inform CGT for men.    
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 However, there is currently limited knowledge of the overall prevalence of HCS in families where 
probands report a PCa FHx, particularly from female and male probands encompassing racial diversity.  While 
prior studies have reported on the impact of PCa FHx on the risk of breast cancer development,17 data from 
cancer genetics programs encompassing a spectrum of patients seeking hereditary cancer assessment are 
needed to gain deeper insights into the rates of HCS in families reporting a FHx of PCa. Furthermore, there is 
virtually no data in racially diverse patient populations regarding rates of HCS from probands presenting for 
genetic assessment who report a PCa FHx. African Americans (AA) in general have been reported to have 
lower rates of uptake and negative views of genetic testing,18-20 which hinders insights into genetic 
contribution to PCa risk and may limit the benefit of genetic assessment in these families.  Expert consensus 
opinion has stressed the need to engage AA men in genetic evaluation for broader knowledge of PCa 
predisposition and aggressiveness,4 which would be strengthened by knowledge of the link of PCa to HCS in 
AA families.  
 Here we report the prevalence of HCS in proband families who reported a FHx of PCa when seeking 
hereditary cancer assessment at an academic cancer genetics program. We assessed rates of HCS with 
plausible genetic link to a reported family member with PCa to uncover the magnitude of the need to discuss 
CGT with men. In particular, we report these rates of HCS by race, which is a current gap in the literature. We 
furthermore report on the rates of germline mutations identified in probands who underwent genetic testing 
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 This study included probands from an overall cohort of patients presenting for inherited cancer 
evaluation and discussed at a Genetics Case Conference as part of the Cancer Risk Assessment and Clinical 
Cancer Genetics Program at Sidney Kimmel Cancer Center at Thomas Jefferson University. An IRB-approved 
database including personal history, family history, demographic, race (self-reported) and genetic data has 
been established (IRB #16D.743). Probands with self-reported AA or Caucasian (Wh) race were included in this 
analysis. Pedigrees of probands were constructed as part of their evaluation, and those who reported with a 
FHx of PCa were selected for this analysis.  Criteria for meeting one of three HCS were evaluated based upon 
proband personal and FHx as follows: HBOC (NCCN Guidelines BRCA1/2 testing criteria, version 2.2017),21 
Hereditary Prostate Cancer (HPC) (Hopkins Criteria),22 or Lynch Syndrome (LS) (Revised Bethesda Criteria).23 
Plausible genetic link of the family member with PCa to any of the HCS identified in a particular pedigree was 
determined if the family member with PCa was:  (1) a blood relative on the same side of the family meeting 
HCS criteria (paternal vs. maternal) or (2) a blood relative to the proband if the proband alone met HCS 
criteria. As per standard cancer genetics practice, probands had undergone genetic counseling with options 
for genetic testing discussed including focused cancer panel or large cancer panel.18,24 If the proband 
underwent genetic testing, then genetic mutations identified in the proband and/or the family were also 
collected and reported.   
 Demographic characteristics of the probands were summarized with counts and percentages or means 
and standard deviations. Associations between HCS (presence or absence) and race were evaluated using 
Fisher’s exact test. Associations between HCS linked to PCA FHx and race were also evaluated using Fisher’s 
exact test, in the subset of subjects meeting criteria for each HCS. All analyses were performed in SAS 9.4 (SAS 
Institute Inc., Cary, NC). 
 
 




 As of July 1, 2017, 1435 patients had presented for inherited cancer evaluation to the Cancer Risk 
Assessment and Clinical Cancer Genetics Program and were discussed at the Genetics Case Conference.  
Among these, 345 probands reported a FHx of PCa (84.6% Wh and 15.4% AA).  Table 1 highlights the 
demographics of the cohort, and Figure 1 shows the flow of participant data and results for this report. Most 
probands were female (74.5%). The most common cancers in probands overall were breast cancer (43.2%) 
and PCa (12.8%). FHx of PCa was reported on the paternal side in 64.9% of probands, on the maternal side in 
34.8%, and within the nuclear family of the proband in 13.0%. 
 Of the 345 probands reporting a FHx of PCa, 79.4% (n=274) met criteria for at least one HCS based on 
their personal cancer history and/or family cancer history (Table 2). The most common HCS pattern was for 
HBOC (71.3%), followed by LS (10.4%), and then HPC (8.4%). No significant differences were seen in overall or 
specific HCS rates between AA and Wh pedigrees (83.0% vs. 78.8%, respectively, p = 0.58) (Table 2).   
 The potential genetic link of the HCS identified in proband families to the family member with PCa was 
assessed and shown in Table 3, as well as highlighted by examples in Figure 2. Overall, 220 probands (63.8% of 
the entire cohort) met criteria for at least one HCS with a plausible genetic link to the reported family member 
with PCa, with 75.5% among AA probands and 61.6% among Wh probands.  Among probands meeting criteria 
for HBOC, a linked FHx of PCa was identified in a higher percentage of AA families compared to Wh families 
(90.2% vs. 74.6%, respectively; p=0.04). While not significant, a similar trend was identified for HCS overall 
(90.9% of AA probands vs. 78.3% of Wh probands; p = 0.06). There was no significant difference in having a 
linked FHx of PCa based on race among probands meeting criteria for HPC or LS (Table 3). 
 Among probands with a HCS with a plausible genetic link to the family member with PCa who 
underwent germline testing (n=169), mutations were identified in 19.5%, with BRCA1/2 mutations most 
commonly identified (10.1%), followed by mutations in CHEK2 (4.7%), PALB2 (1.2%), MSH2 (1.2), APC (0.6%), 
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ATM (0.6%), MUTYH (0.6%), and PMS2 (0.6%)(Table 4).  While BRCA1/2 mutations accounted for all mutations 
identified in AA probands (n=5), a spectrum of mutations were identified in Wh probands (n=28) including in 
CHEK2, MSH2, PALB2, APC, ATM, MUTYH, and PMS2 (Table 4).  
 
DISCUSSION 
 Genetic evaluation for hereditary cancer risk involves factoring in family cancer history, personal 
cancer history, and germline genetic testing of male and female probands to inform cancer screening, risk 
reduction, and precision medicine recommendations for probands.4,10,24 However, there are broader 
implications of hereditary cancer assessment for family members regarding CGT if genetic mutations are 
identified in probands. With the growing recognition of the connection of PCa with specific HCS,1,3,4 men with 
PCa in families meeting HCS criteria can benefit from appropriate CGT when mutations are identified in 
probands as well as family history-based recommendations. However, there is a lack of data regarding the 
prevalence of potential PCa connection to HCS in diverse families and the mutation spectrum in probands that 
may inform CGT for men with PCa. These data are particularly lacking in AA families, where uncovering the 
prevalence of HCS and germline mutations will lend support to developing strategies to increase awareness of 
genetic evaluation among AAs.  
 Our study in a comprehensive academic cancer genetics program found that a significant percentage of 
probands (63.8%) who presented for inherited cancer assessment with a FHx of PCa met criteria for a 
hereditary cancer syndrome where the family member with PCa may have had a plausible genetic link to the 
HCS in the family. Of further interest, HBOC was identified in a higher percentage of AA families with a 
potentially linked PCa compared to Wh families (p = 0.04).  This is the first report to our knowledge to show 
that AA probands with a FHx of PCa have a higher chance of meeting criteria for HBOC, with implications for 
proband genetic testing, downstream CGT of AA men with PCa, and family history-based recommendations for 
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men. Even if probands test negative, men with PCa in these families with suspected HCS may be 
recommended to undergo their own genetic testing.24  Family history-based recommendations are also 
important for all blood relatives particularly when there is a suspected HCS with uninformative genetic 
testing.4,8,24 Therefore, men with PCa in families where probands may present for cancer concerns even other 
than PCa can be benefited by family history-based recommendations for cancer screening or pursue their own 
genetic testing.24  
 Though our sample size was small, our findings show that BRCA1/2 mutations accounted for all 
mutations identified in AA probands while a spectrum of mutations were identified in Wh probands including 
in CHEK2, MSH2, PALB2, APC, ATM, MUTYH, and PMS2. Our findings point to the need for greater engagement 
of AA families in genetic evaluation to broaden our insights into the genetic predisposition to cancers affecting 
females and males in families.  Germline mutations in families reporting a FHx of PCa further highlight the 
need to develop strategies to address communication of cancer genetic evaluation across genders, with 
particular focus needed in AA families.  CGT of men with PCa has major emerging implications for precision 
therapy. Olaparib was given “Breakthrough Therapy” designation by the United States FDA for BRCA1/2- or 
ATM-positive  metastatic castration-resistant PCa (mCRPC) based on Phase II data from the TOPARP-A trial 
demonstrating improved responses particularly in a subset of patients with DNA repair mutations.25 Recently, 
rucaparib was also granted “Breakthrough Therapy” designation for men with BRCA1/2-positive mCRPC 
following at least one androgen receptor–directed therapy and taxane-based chemotherapy based on Phase II 
data from the TRITON2 study.26 Furthermore, BRCA2 status may inform treatment sequencing in men with 
mCRPC.27  BRCA and ATM mutations are also beginning to inform active surveillance in men with early stage 
PCa.28 Therefore, identification of men with PCa in families with suspected HCS and germline mutations can 
inform precision therapy or management for men with PCa which again needs to be specifically addressed in 
AA families as our data highlight. Genetic results inform additional cancer risks in families, where guidelines 
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for cancer screening exist for several genes.  For example, cancer risks associated with BRCA mutations include 
PCa, pancreatic cancer, male breast cancer, and melanoma for men. Female cancer risks include breast cancer, 
ovarian cancer, pancreatic cancer, and melanoma which all warrant discussion of cancer screening, high-risk 
consultation, and/or risk reducing recommendations.8 These discussions need special attention in AA families 
to ensure appropriate CGT of men with PCa and other blood relatives to inform cancer screening and cancer 
risk reduction measures.  
 A spectrum of germline mutations was observed in Wh probands beyond BRCA, which has implications 
for CGT in genetically-linked men with PCa in these families. In addition to the cancer risks associated with 
BRCA mutations, pathogenic variants in CHEK2, MSH2, PALB2, APC, ATM, MUTYH, and PMS2 confer a host of 
cancer risks for male carriers including colorectal cancer, pancreatic cancer, and small bowel cancer which 
may be relevant for men with PCa who are in survivorship for heightened cancer screening.8,10,24 For men with 
mCRPC, genetic results from CGT may inform therapeutic options for PARP inhibition and also for 
immunotherapy.25,29  
 There are some limitations to note. The population in this analysis was enriched for patients with a 
high likelihood of HCS, as all patients were specifically referred for genetic testing and therefore the rates of 
HCS may be higher than the general population. Additionally, despite the fact that the referral base for this 
study is a population with a higher AA population than other parts of the country, AA probands represented 
15.4% of this study, which highlights the need to engage AAs in genetic evaluation discussions and could have 
inflated the rates of HCS in AA participants in our study.    Family history information was by proband self-
report, which is a known limitation in cancer genetic studies as well.30  Self-reported FHx was also limited 
regarding information of clinically significant PCa, which is a part of NCCN guidelines informing genetic 
testing.8,9 Genetic testing in our cohort encompassed focused gene testing and large panel testing based on 
patient decisions after genetic counseling, which may have influenced our findings.  The overall number of AA 
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probands who underwent genetic testing was also limited (n=28), of whom five were found to carry BRCA 1/2 
mutations.  While this implicates BRCA mutations in AA families with HCS linked with PCA, there remains a 
need for broader testing to uncover the genetic spectrum in AA families. A strength of our study is the large 
percentage of female probands included in the analysis, which begins to address the gender divide regarding 
cancer genetic testing and communication of genetic results in families with attention to diversity.  
 
CONCLUSION 
A significant percentage of patients who present for inherited cancer assessment with a FHx of PCa meet 
criteria for a HCS with a plausible genetic link to a family member with PCa. AA probands with a PCa FHx have 
substantial rates of HCS with a subset having BRCA mutations identified, thus having CGT implications for men 
with PCa in these families.  Cascade testing for men with PCa in families presenting with a broad spectrum of 
cancers is crucial to inform cancer screening, precision therapy, and precision management of men with PCa. 
Greater research is needed to optimize communication of cancer risk and genetic testing across genders with 
attention to patient diversity.  
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